Peter Probst

Peter Probst Email and Phone Number

Senior Director Immuno-Oncology at OncoResponse Inc.
Peter Probst's Location
Seattle, Washington, United States, United States
Peter Probst's Contact Details
About Peter Probst

I am a highly motivated, innovative, strategic and compassionate leader with over 25 years of biotech experience in discovering and developing immunomodulatory therapeutics that benefit patients suffering from cancer, autoimmune and chronic infectious diseases. The programs I led include small molecules immune response modifiers and biologics for autoimmune and inflammatory diseases as well as immune-oncology therapeutics modulating the tumor microenvironment, and enhancing anti-cancer T cell responses.In my recent role as Senior Director of Immune Oncology (IO) at OncoResponse, I was responsible for the discovery and development of antibodies modulating tumor immune evasion in the tumor microenvironment. Under my leadership, the IO-team completed preclinical, IND-enabling and translational studies to move a first-in class immunomodulatory mAb and a best-in-class mAb into the clinic

Peter Probst's Current Company Details

Senior Director Immuno-Oncology at OncoResponse Inc.
Peter Probst Work Experience Details
  • Oncoresponse Inc.
    Senior Director Immuno-Oncology
    Oncoresponse Inc. Jun 2021 - Oct 2023
    Houston, Texas, Us
    •Responsible for antibody discovery, preclinical and translational development of cancer immunotherapy targets modulating the tumor microenvironment and anti-cancer immune responses; achieved first in patient dosing for a First-in-Class mAb program in Q3, 2021 and a Best-in-Class mAb program in Q4, 2023. •Delivered two additional drug development candidates to CMC and incepted a novel T cell engager program for cancer immunotherapy.•Managed and mentored a team of 9 Ph.D. and non-Ph.D. scientists (Research Associate to Director level); increased in vitro/in vivo capabilities and productivity of group to characterize antibodies from hit to lead to clinical development including mAb screening, functional assay, in vivo validation, PK profile assessment, FC-mediated antibody function, ADA and receptor occupancy assays.•Pharmacological and translational medicine liaison writing and reviewing IND-briefing documents, IND-filing modules; Member of clinical core team supporting clinical trial design and patient sample evaluation for PK/PD, receptor occupancy/target engagement and biomarker identification.
  • Oncoresponse Inc.
    Director Immuno-Oncology
    Oncoresponse Inc. Jun 2019 - May 2021
    Houston, Texas, Us
    See above
  • Kineta, Inc.
    Vp And Head Of Immunology
    Kineta, Inc. Jan 2018 - Jun 2019
    Seattle, Wa, Us
  • Kineta, Inc.
    Director And Head Of Immunology
    Kineta, Inc. Nov 2014 - Jan 2018
    Seattle, Wa, Us
    •Scientific co-founder of Kineta Immune-Oncology LLC, built immuno-oncology in vitro and in vivo group to discover and develop immunogenic cell death inducing small molecule RIG-I agonist for cancer immunotherapies; developed project plan for I/O collaboration with pharmaceutical partner; program was licensed to pharmaceutical partner 3 years after inception•Led HTS discovery and SAR program to identify small molecule immune modulators targeting IRF pathways; collaborated with medicinal chemistry to optimize small molecule leads.•Immunology/translational lead on autoimmunity and neuro-inflammation biologic programs; developed novel therapeutic concept for autoimmune program in early clinical development (Phase I/II) targeting pathogenic T cells•Responsible for preclinical development of novel H5N1 influenza vaccine adjuvant•Scientific lead on academic collaborations•Principal Investigator on NCI funded Phase 1 and Phase 2 SBIR grants
  • Independent Consultant
    Principal
    Independent Consultant Aug 2014 - Oct 2014
    Expertise and services:• Drug discovery and preclinical development of immunomodulatory/regulatory small molecule and biologics programs• Vaccine discovery and development• Identification of novel opportunities, due diligence and project risk assessment• Generation and evaluation of client data packages• Assay development• Literature searches
  • Scynexis
    Manager, Immunology
    Scynexis Jun 2012 - Jun 2014
    Jersey City, New Jersey, Us
    • Built immunological capabilities and led immunology team• Characterized novel class of immune response modifiers to treat chronic viral infections and cancer• Performed translational studies for mechanism of action and biomarker assessment• Managed CRO and external collaborations to generate proof of concept data in animal models • Identified novel opportunities for immunomodulatory compounds targeting chronic infectious diseases and cancer• Provided immunological expertise to internal projects, external collaborations and BD opportunities
  • Vlst
    Associate Director
    Vlst Aug 2006 - Feb 2012
    Seattle, Wa, Us
    •Alliance management for external autoimmune and inflammatory disease collaborations•Project leader for early target discovery and lead therapeutic programs •Established in vitro pharmacology group to discover and develop biologic modalities targeting autoimmune or chronically activated T cells for the treatment of autoimmune and inflammatory diseases (A&I)•Successfully developed and executed functional assays focusing on human and murine primary cells to translate viral immune evasion strategies into therapeutic concepts for A&I indications•Collaborated with genetic and bioinformatic colleagues to integrate functional assay data into a biological systems approach to identify targets for A&I •Identified novel mechanism of action for lead therapeutic program which enabled therapeutic concept validation and selection of autoimmune disease indications •Established research objectives and therapeutic concepts for over 20 targets•Developed PK, PD and immunogenicity assays supporting regulatory activities•Provided scientific and competitive intelligence advice for BD activities •Immunology subject matter expert in regulatory/clinical working group•Scientific and technical support for target discovery, therapeutic design, and preclinical in vivo group
  • Corixa Corporation
    Senior Scientist
    Corixa Corporation Jul 1997 - Apr 2006
    •Principal Investigator, Project Leader for NIH contract: ‘Innate Immune Receptors and Adjuvant Discovery’; characterization of synthetic TLR4 agonist/antagonist for monotherapy indications and as vaccine adjuvants•Project Leader for antigen discovery and preclinical development of Chlamydia trachomatis vaccine; Successfully transitioned program to pharmaceutical partner 5 years after initiation; responsible for the preclinical development of a Chlamydia vaccine including inception of vaccine concept, vaccine discovery by T cell expression, lead selection.•Characterized the effects of synthetic TLR4 agonists/antagonists and microbial immunomodulatory proteins on human monocytes, macrophages, and dendritic cells
  • Corixa Corporation
    Postdoctoral Fellow
    Corixa Corporation Jan 1997 - Jun 1997
    • Established program to characterize effects of microbial immunomodulatory proteins on human macrophages and dendritic cells
  • Infectious Disease Research Institute
    Research Fellowship
    Infectious Disease Research Institute Jan 1995 - Dec 1996
    Research Fellowship provided by the Deutsche Forschungsgemeinschaft (German Research Association) to perform research at the Infectious Disease Research Institute (Seattle, Washington)•Generated human leishmanial antigen-specific T cell lines by infecting dendritic cells with Leishmania major •Identified and characterized leishmanial vaccine candidates by human T cell expression cloning.•Characterized the immunomodulatory effects of leishmanial proteins on human primary immune cells

Peter Probst Skills

Immunology Drug Discovery Assay Development Infectious Diseases Biotechnology In Vitro Clinical Development In Vivo Vaccines Cell Culture Inflammation Microbiology Cell Molecular Biology Biologics Preclinical Development Autoimmune Diseases Collaboration Management Adjuvants Life Sciences Cellular Immunology Immune Modulation Viral Immune Evasion

Peter Probst Education Details

  • Johannes Gutenberg University Mainz
    Johannes Gutenberg University Mainz
    Microbiology

Frequently Asked Questions about Peter Probst

What is Peter Probst's role at the current company?

Peter Probst's current role is Senior Director Immuno-Oncology at OncoResponse Inc..

What is Peter Probst's email address?

Peter Probst's email address is pp****@****bio.com

What is Peter Probst's direct phone number?

Peter Probst's direct phone number is +191920*****

What schools did Peter Probst attend?

Peter Probst attended Johannes Gutenberg University Mainz.

What skills is Peter Probst known for?

Peter Probst has skills like Immunology, Drug Discovery, Assay Development, Infectious Diseases, Biotechnology, In Vitro, Clinical Development, In Vivo, Vaccines, Cell Culture, Inflammation, Microbiology.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.